ZYME: Roche deal funds ZW209 as ZW191 and ZIIHERA data strengthen pipeline
A Roche deal funds ZW209 development while keeping milestone and royalty upside, and new ZW191 and ZIIHERA data strengthen the portfolio, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
ZYME said a deal with Roche funds development of ZW209 while preserving potential milestone payments and royalty upside, according to TradingView. ZW191 showed activity at both doses in patients with heavily pretreated ovarian cancer. The partner also reported a 27-month median overall survival for the ZIIHERA triplet in first-line advanced gastroesophageal adenocarcinoma, a summary that the source notes may contain inaccuracies.
why it matters
For investors this is mainly a company-level story: outside funding eases part of the cost of developing ZW209, while clinical results shape expectations for future licensing and royalty income. Such data rarely moves the broader market.
tags
instruments
sources
- ZYME: Roche-backed ZW209 advances as ZW191 and ZIIHERA data strengthen the portfolio — TradingView, 27 October 2026 at 23:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗